Driving Robust Tolerance with Multi-Cargo Lipid Nanoparticles to Advance Safe, Targeted, & Durable Therapeutic Responses

• Explore the updates from our Intergrated Nanotherapeutics T1D preclinical program to understand the therapeutic potential of multi-cargo lipid nanoparticles in antigen- specific immune tolerance
• Demonstrate the translation of antigen selection from preclinical models to the clinic to support more effective and clinically relevant therapeutic design

Speakers:

Heather Denroche

Co-founder and Director of Preclinical Development

Integrated Nanotherapeutics Inc.